Lilly Wows ADA Crowd With Obesity Data Across Three-Drug Incretin Portfolio

Weight Loss Of Up To 24.2% With ‘Triple G’ Retatrutide

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Lilly may gain its first US approval in obesity with Mounjaro before the end of 2023, but presented data at ADA for it and two other drugs – retatrutide and orforglipron – that also yielded significant weight loss.

Black and white scale on wood floor
Lilly presented data at ADA on three obesity drugs • Source: Shutterstock

Eli Lilly and Company is a few years behind Novo Nordisk A/S in bringing a GLP-1 agonist to market for obesity, but it presented data at the American Diabetes Association (ADA) annual meeting that could give the company a best-in-class portfolio of medicines, including its GLP-1/GIP/glucagon receptor (GGG) triagonist retatrutide, which generated weight loss of up to 24.2% in overweight and obese patients without diabetes at 48 weeks in a Phase II clinical trial presented on 26 June.

Novo Nordisk already markets the injectable GLP-1 agonist Wegovy (semaglutide) for obesity in the US and plans to submit its...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D